B-Vaxx was mentioned in the Pharma Letter as one of the VAX in trials. But not in the 4C, maybe because it is financed by US comps/government Uni Grants.
Anyway, focus is on Her, PD1 and CF33 which should catapult IMU into a recognized pharma orbit.
GLTA
Ann: Appendix 4C - quarterly, page-6
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.9¢ |
Change
0.001(2.08%) |
Mkt cap ! $356.9M | |||
| Open | High | Low | Value | Volume |
| 4.9¢ | 4.9¢ | 4.8¢ | $158.1K | 3.254M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 70 | 7836950 | 4.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.9¢ | 2431104 | 24 |
View Market Depth
| Last trade - 13.22pm 04/10/2024 (20 minute delay) ? |
| IMU (ASX) Chart |